An anti-Axl monoclonal antibody attenuates xenograft tumor growth and enhances the effect of multiple anticancer therapies
- 5 July 2010
- journal article
- research article
- Published by Springer Science and Business Media LLC in Oncogene
- Vol. 29 (38), 5254-5264
- https://doi.org/10.1038/onc.2010.268
Abstract
Axl is expressed in various types of cancer and is involved in multiple processes of tumorigenesis, including promoting tumor cell growth, migration, invasion, metastasis as well as angiogenesis. To evaluate further the mechanisms involved in the expression/activation of Axl in various aspects of tumorigenesis, especially its roles in modulating tumor stromal functions, we have developed a phage-derived mAb (YW327.6S2) that recognizes both human and murine Axl. YW327.6S2 binds to both human and murine Axl with high affinity. It blocks the ligand Gas6 binding to the receptor, downregulates receptor expression, inhibits receptor activation and downstream signaling. In A549 non-small-cell lung cancer (NSCLC) and MDA-MB-231 breast cancer models, YW327.6S2 attenuates xenograft tumor growth and potentiates the effect of anti-VEGF treatment. In NSCLC models, YW327.6S2 also enhances the effect of erlotinib and chemotherapy in reducing tumor growth. Furthermore, YW327.6S2 reduces the metastasis of MDA-MB-231 breast cancer cells to distant organs. YW327.6S2 induces tumor cell apoptosis in NSCLC, reduces tumor-associated vascular density and inhibits the secretion of inflammatory cytokines and chemokines from tumor-associated macrophages in the breast cancer model. In conclusion, anti-Axl mAb can enhance the therapeutic efficacy of anti-VEGF, EGFR small-molecule inhibitors as well as chemotherapy. Axl mAb affects not only tumor cells but also tumor stroma through its modulation of tumor-associated vasculature and immune cell functions.Keywords
This publication has 41 references indexed in Scilit:
- Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survivalProceedings of the National Academy of Sciences of the United States of America, 2009
- Axl promotes cell invasion by inducing MMP-9 activity through activation of NF-κB and Brg-1Oncogene, 2008
- Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survivalProceedings of the National Academy of Sciences of the United States of America, 2006
- Erlotinib in Lung Cancer — Molecular and Clinical Predictors of OutcomeNew England Journal of Medicine, 2005
- High-affinity Human Antibodies from Phage-displayed Synthetic Fab Libraries with a Single Framework ScaffoldJournal of Molecular Biology, 2004
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib TherapyScience, 2004
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to GefitinibNew England Journal of Medicine, 2004
- Phage-displayed Antibody Libraries of Synthetic Heavy Chain Complementarity Determining RegionsJournal of Molecular Biology, 2004
- Tumour-educated macrophages promote tumour progression and metastasisNature Reviews Cancer, 2004
- Inflammation and cancerNature, 2002